Author:
Chung Byung Ha,Horie Shigeo,Chiong Edmund
Funder
Takeda Pharmaceutical Company Ltd
Sanofi
Astellas Pharma
AstraZeneca
Janssen Pharmaceutica
Takeda Pharmaceutical Company Ltd.
Bayer
Pfizer
Roche
Myovant Sciences GmbH
Ipsen
JW Pharmaceutical
Handok
Amgen
MediTech Media Asia Pacific
Takeda Pharmaceutical Company
Reference31 articles.
1. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist;Tsushima;Urol Int,2001
2. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study;You;Scand J Urol Nephrol,2010
3. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan;Suzuki;Jpn J Clin Oncol,2015
4. Leuprorelin acetate product information (Australia) Canberra: TGA;Goods Administration,2017
5. Leuprorelin (Leuplin Pro) product information (Japan);Takeda Pharmacutical Company Ltd,2016
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献